Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An increased FGFR1 gene copy number was found in 32 (32%) lung cancer patients.
|
22179561 |
2012 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the significance of FGFR1 in lung cancer, we analysed tumours by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
|
22648708 |
2012 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides novel epidemiologic data through identification of FGFR1 gene amplification in Chinese NSCLC specimens (particularly squamous) and, importantly, extends the clinical significance of this finding by using multiple FGFR1-amplified squamous lung cancer PDTX models to show tumor stasis or regression effects using a specific FGFR inhibitor (AZD4547).
|
23082000 |
2012 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We identified four cell lines and two newly established primary lung cancer cultures that showed high FGFR1 expression levels, and evaluated the effect of the novel FGFR1 inhibitor ponatinib on cell growth.
|
23563700 |
2013 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene amplification of FGFR1 occurs in lung cancer and estrogen receptor (ER)-positive breast cancer, and that of FGFR2 in diffuse-type gastric cancer and triple-negative breast cancer.
|
23696246 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.
|
24183471 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amplification of FGFR1 is one of the most frequent candidate targets in lung cancer.
|
24302556 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
FGFR1 FISH and SISH were performed in 406 and 385 lung cancer cases, respectively, and the results were compared.
|
24762544 |
2014 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A tissue microarray composed of resected lung tumors was submitted to FGFR1 GCN, and mRNA analyses and the results were validated with The Cancer Genome Atlas (TCGA) lung cancer data.
|
24771645 |
2014 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The lung cancer appeared to remain in the stasis phase for 2 years and then burst to stage IV with the amplification of the fibroblast growth factor receptor 1 gene.
|
25918980 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we deployed RNAi-based functional genomic screens to identify protein kinases controlling the intrinsic sensitivity of FGFR1-dependent lung cancer and head and neck squamous cell cancer (HNSCC) cells to ponatinib, a multikinase FGFR-active inhibitor.
|
26359452 |
2015 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Large-scale genomics have recently expanded the lung cancer landscape with FGFR1 amplification found in 10-20% of squamous cell carcinomas (SCCs).
|
26549034 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together our study suggests that the FGFR1/GLI2 axis promotes the lung cancer stem cell-like phenotype.
|
26936993 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
FGFR1 amplification was identified in all types of lung carcinoma.
|
27194548 |
2016 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer.
|
27245147 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that FGFR1 can mediate adaptive resistance to trametinib and validate a combinatorial approach for treating KRAS-mutant lung cancer.
|
27338794 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phosphorylation of Pyruvate Kinase M2 (PKM2) on Tyr105 by fibroblast growth factor receptor 1 (FGFR1) has been shown to promote its nuclear localization as well as cell growth in lung cancer.
|
28418088 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-Affinity Internalizing Human scFv-Fc Antibody for Targeting FGFR1-Overexpressing Lung Cancer.
|
28483948 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a consequence, we demonstrate that rational combination therapies resensitize resistant cells to treatment with FGFR inhibitors.<b>Conclusions:</b> We provide evidence for the existence of diverse mechanisms of primary drug resistance in <i>FGFR1</i>-amplified lung cancer and provide a rational strategy to improve FGFR inhibitor therapies by combination treatment.<i></i>.
|
28630215 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Basic fibroblast growth factor (bFGF) and fibroblast growth factor receptor 1 (FGFR1) are associated with drug resistance in lung cancer.
|
28765892 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we identified the roles of alternative receptor tyrosine kinases (RTKs) in FGFR1-amplified lung cancer.
|
28968756 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A stable lentiviral FGFR1 over-expression system in lung cancer cells is described for the study of anti-lung cancer drug candidates targeting FGFR1.
|
29281903 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined targeting of YAP1 and FGFR1 may provide benefits to patients with FGFR1-amplified lung cancer.
|
29452146 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that activation of FGFR1 by its ligand fibroblast growth factor 2 (FGF2) promoted proliferation, EMT, migration, and invasion in FGFR1-amplified lung cancer cell lines H1581 and DMS114, whereas inhibition of FGFR1 suppressed these processes.
|
29858603 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we identified a FGFR1 inhibitory peptide R1-P2 and investigated its effects on the lung cancer cells growth and angiogenesis <i>in vitro</i> and <i>in vivo</i>.
|
30123084 |
2018 |